Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Inhibitor Brings New Hope

14.09.2017

Researchers found a possible new treatment for aggressive triple receptor-negative breast cancer

Scientists from the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg and the Freiburg University Medical Center have shown that inhibiting the epigenetic regulator KDM4 might offer a potential novel treatment option for breast cancer patients.


Breast cancer stem cell line 1 (BCSC1) from the newly established cell model. Here we can see the proteins keratin 5 in green and keratin 8 in red, with the nucleus in blue.

Source: Maurer Lab

They used a newly established cell model that enables scientists to isolate cancer stem cells directly from patient tumor. Using this special culture system, they were able to test potential new cancer drugs. One of these, a novel inhibitor of the epigenetic regulator KDM4, co-developed in the lab of Prof. Schüle, showed promising results. The researchers now published their work in the scientific journal Cancer Research.

Although the prognosis for breast cancer has been steadily improving in the last decades, patients with triple receptor-negative breast cancer form a subgroup who receive a considerably worse prognosis in most cases. Roughly 15 percent of all breast cancer patients have triple receptor-negative breast cancer, which lacks markers for a targeted therapy.

In the last few years, a bulk of data pointing to a small population of cells in tumors that maintain tumor growth, are particularly resistant to chemotherapy, are responsible for relapses, and develop metastases. These cells, named cancer stem-like cells, share many characteristics with the body’s normal stem cells. Due to their cancer-driving behavior, researchers have been focusing more and more on targeting these cells. However, there are currently only a few models available to study the biology of cancer stem cells.

Scientists from the University of Freiburg's new Center for Translational Cell Research have developed a model that allows scientists to isolate cancer stem cells from tumors obtained from breast cancer patients, thereby making biochemical and molecular analysis much more feasible.

Dr. Jochen Maurer and his research group were able to cultivate several cancer stem cell lines from triple receptor-negative breast cancer that are excellent representations of the original tumors they isolated from the patients.

In collaboration with Prof. Dr. Roland Schüle and his team at the Center of Clinical Research of the Freiburg University Medical Center, the scientists were able to test several epigenetic inhibitors that had been newly developed by Schüle and his team on the cancer stem cell model.

Epigenetics relates to the regulation of genes without involving changes in the DNA sequence and is regarded as one of the most important issues of the 21st century. It is believed that epigenetics play a huge role in the development and progression of cancer.

Schüle and his team have already conducted well-known studies on the epigenetic regulator LSD1. Now, they have discovered that an inhibitor of the epigenetic regulator KDM4 shows great promise in modulating breast cancer stem cell pathology.

They were able to block proliferation of several cancer stem cell lines. In addition, the KDM4 inhibitor induces a change of the molecular make-up of the cancer stem cells and drives them out of stemness. Finally, they were also able to reduce tumor growth in their first in vivo xenograft analysis.

Original Publication:
Metzger, E., Stepputtis, S.S., Strietz, J., Preca, B.T., Urban, S., Willmann, D., Allen, A., Zenk, F., Iovino, N., Bronsert, P., Proske, A., Follo, M., Boerries, M., Stickeler, E., Xu, J., Wallace, M.B., Stafford, J., Kanouni, T., Maurer, J., Schüle, R. (2017): KDM4 inhibition targets breast cancer stem-like cells. Cancer Research.
DOI: 10.1158/0008-5472.CAN-17-1754

Caption:
Breast cancer stem cell line 1 (BCSC1) from the newly established cell model. Here we can see the proteins keratin 5 in green and keratin 8 in red, with the nucleus in blue.
Source: Maurer Lab

Contact:
Prof. Dr. Roland Schüle
Department of Urology and the Center of Clinical Research
Freiburg University Medical Center
BIOSS Centre for Biological Signalling Studies
Phone: +49 (0)761 / 203 - 63100
E-Mail: roland.schuele@uniklinik-freiburg.de

Dr. Jochen Maurer
Department of Visceral Surgery and Zentrum für Translationale Zellforschung
Freiburg University Medical Center
Tel.: 0761/270-63570
E-Mail: jochen.maurer@uniklinik-freiburg.de

Weitere Informationen:

https://www.pr.uni-freiburg.de/pm-en/2017/new-inhibitor-brings-new-hope

Rudolf-Werner Dreier | idw - Informationsdienst Wissenschaft
Further information:
http://www.uni-freiburg.de/

More articles from Life Sciences:

nachricht Study of transplanted hearts reveals risk gene for cardiovascular disease
14.09.2017 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

nachricht Multifunctional nano-sized drug carriers based on reactive polypept(o)ides
13.09.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

Im Focus: Using Mirrors to Improve the Quality of Light Particles

Scientists from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute have succeeded in dramatically improving the quality of individual photons generated by a quantum system. The scientists have successfully put a 10-year-old theoretical prediction into practice. With their paper, published recently in Physical Review X, they have taken an important step towards future applications in quantum information technology.

For a number of years, scientists have been working on using electron spins to store and process information. A possible approach is to use a quantum system in...

Im Focus: High-speed Quantum Memory for Photons

Physicists from the University of Basel have developed a memory that can store photons. These quantum particles travel at the speed of light and are thus suitable for high-speed data transfer. The researchers were able to store them in an atomic vapor and read them out again later without altering their quantum mechanical properties too much. This memory technology is simple and fast and it could find application in a future quantum Internet. The journal Physical Review Letters has published the results.

Even today, fast data transfer in telecommunication networks employs short light pulses. Ultra broadband technology uses optical fiber links through which...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

IVAM’s LaserForum visits the Swiss canton of St. Gallen with the topic ultrashort pulse lasers

06.09.2017 | Event News

 
Latest News

Asthma drug from the garden center

14.09.2017 | Health and Medicine

New Inhibitor Brings New Hope

14.09.2017 | Life Sciences

Study of transplanted hearts reveals risk gene for cardiovascular disease

14.09.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>